Suppression of Asparaginyl Endopeptidase Attenuates Breast Cancer-induced Bone Pain Through Inhibition of Neurotrophin Receptors

Overview

Journal Mol Pain

Date 2017 May 31

PMID 28554249

Citations 7

Authors

Peng Yao

Yuanyuan Ding

Zhenkai Han

Ying Mu

Tao Hong

Yongqiang Zhu

Hongxi Li

Affiliations

Soon will be listed here.

Abstract

Objective Cancer-induced bone pain is a common clinical problem in breast cancer patients with bone metastasis. However, the mechanisms driving cancer-induced bone pain are poorly known. Recent studies show that a novel protease, asparaginyl endopeptidase (AEP) plays crucial roles in breast cancer metastasis and progression. We aim to determine the functions and targeted suppress of AEP in a mouse model of breast cancer-induced bone pain. Methods Breast cancer cells with AEP knocked-down or overexpression were constructed and implanted into the intramedullary space of the femur to induce pain-like behavior in mice. AEP-specific inhibitors or purified AEP proteins were further used in animal model. The histological characters of femur and pain ethological changes were measured. The expressions of AEP and neurotrophin receptors (p75NTR and TrkA) in dorsal root ganglion and spinal cord were examined. Results Femur radiographs and histological analysis revealed that cells with AEP knocked-down reduced bone destruction and pain behaviors. However, cells with AEP overexpression elevated bone damage and pain behaviors. Further, Western blot results found that the expressions of p75NTR and TrkA in dorsal root ganglions and spinal cords were reduced in mice inoculated with AEP knocked-down cells. Targeted suppression of AEP with specific small compounds significantly reduced the bone pain while purified recombinant AEP proteins increased bone pain. Conclusions AEP aggravate the development of breast cancer bone metastasis and bone pain by increasing the expression of neurotrophin receptors. AEP might be an effective target for treatment of breast cancerinduced bone pain.

Citing Articles

Oral Cancer Cells Release Vesicles that Cause Pain.

Dubeykovskaya Z, Tu N, Garcia P, Schmidt B, Albertson D Adv Biol (Weinh). 2022; 6(9):e2200073.

PMID: 35802912 PMC: 9474716. DOI: 10.1002/adbi.202200073.

Usefulness of the measurement of neurite outgrowth of primary sensory neurons to study cancer-related painful complications.

Park S, Eber M, Fonseca M, Patel C, Cunnane K, Ding H Biochem Pharmacol. 2021; 188:114520.

PMID: 33741328 PMC: 8154668. DOI: 10.1016/j.bcp.2021.114520.

Target Enzymes Considered for the Treatment of Alzheimer's Disease and Parkinson's Disease.

Kim N, Lee H Biomed Res Int. 2020; 2020:2010728.

PMID: 33224974 PMC: 7669341. DOI: 10.1155/2020/2010728.

Legumain Induces Oral Cancer Pain by Biased Agonism of Protease-Activated Receptor-2.

Tu N, Jensen D, Anderson B, Chen E, Jimenez-Vargas N, Scheff N J Neurosci. 2020; 41(1):193-210.

PMID: 33172978 PMC: 7786216. DOI: 10.1523/JNEUROSCI.1211-20.2020.

Down-Regulation of NOX4 Expression in Dorsal Horn of Spinal Cord Could Alleviate Cancer-Induced Bone Pain in Rats by Reducing Oxidative Stress Response.

Long H, Zheng H, Ai L, Osman K, Liu Z Cancer Manag Res. 2020; 12:10929-10938.

PMID: 33154672 PMC: 7608490. DOI: 10.2147/CMAR.S263177.

References

Dilara Savci-Heijink C, Halfwerk H, Koster J, van de Vijver M . A novel gene expression signature for bone metastasis in breast carcinomas. Breast Cancer Res Treat. 2016; 156(2):249-59. PMC: 4819548. DOI: 10.1007/s10549-016-3741-z. View

Choi S, Reddy S, Devlin R, Menaa C, Chung H, Boyce B . Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption. J Biol Chem. 1999; 274(39):27747-53. DOI: 10.1074/jbc.274.39.27747. View

King T, Vardanyan A, Majuta L, Melemedjian O, Nagle R, Cress A . Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain. 2007; 132(1-2):154-68. PMC: 2704581. DOI: 10.1016/j.pain.2007.06.026. View

Chaplan S, Bach F, Pogrel J, Chung J, Yaksh T . Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994; 53(1):55-63. DOI: 10.1016/0165-0270(94)90144-9. View

Zhang Z, Xie M, Ye K . Asparagine endopeptidase is an innovative therapeutic target for neurodegenerative diseases. Expert Opin Ther Targets. 2016; 20(10):1237-45. PMC: 5315368. DOI: 10.1080/14728222.2016.1182990. View

Gotz M, James K, Hansell E, Dvorak J, Seshaadri A, Sojka D . Aza-peptidyl Michael acceptors. A new class of potent and selective inhibitors of asparaginyl endopeptidases (legumains) from evolutionarily diverse pathogens. J Med Chem. 2008; 51(9):2816-32. DOI: 10.1021/jm701311r. View

Gawenda J, Traub F, Luck H, Kreipe H, von Wasielewski R . Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat. 2006; 102(1):1-6. DOI: 10.1007/s10549-006-9311-z. View

Xu C, Cao L, Liu J, Qian Z, Peng Y, Zhu W . Suppression of Asparaginyl Endopeptidase Inhibits Polyomavirus Middle T Antigen-Induced Tumor Formation and Metastasis. Oncol Res. 2016; 25(3):407-415. PMC: 7841005. DOI: 10.3727/096504016X14743350548249. View

Sevcik M, Ghilardi J, Peters C, Lindsay T, Halvorson K, Jonas B . Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain. 2005; 115(1-2):128-41. DOI: 10.1016/j.pain.2005.02.022. View

10.

Biernat W, Kleihues P, Yonekawa Y, Ohgaki H . Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol. 1997; 56(2):180-5. DOI: 10.1097/00005072-199702000-00009. View

11.

Liu C, Sun C, Huang H, Janda K, Edgington T . Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 2003; 63(11):2957-64. View

12.

Yao P, Ding Y, Wang Z, Ma J, Hong T, Zhu Y . Impacts of anti-nerve growth factor antibody on pain-related behaviors and expressions of opioid receptor in spinal dorsal horn and dorsal root ganglia of rats with cancer-induced bone pain. Mol Pain. 2016; 12. PMC: 4955994. DOI: 10.1177/1744806916644928. View

13.

Chakravarthy R, Mnich K, Gorman A . Nerve growth factor (NGF)-mediated regulation of p75(NTR) expression contributes to chemotherapeutic resistance in triple negative breast cancer cells. Biochem Biophys Res Commun. 2016; 478(4):1541-7. DOI: 10.1016/j.bbrc.2016.08.149. View

14.

Bloom A, Jimenez-Andrade J, Taylor R, Castaneda-Corral G, Kaczmarska M, Freeman K . Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers. J Pain. 2011; 12(6):698-711. PMC: 3111843. DOI: 10.1016/j.jpain.2010.12.016. View

15.

Choi S, Kurihara N, Oba Y, Roodman G . Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. J Bone Miner Res. 2001; 16(10):1804-11. DOI: 10.1359/jbmr.2001.16.10.1804. View

16.

Hefti F, Rosenthal A, Walicke P, Wyatt S, Vergara G, Shelton D . Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci. 2005; 27(2):85-91. DOI: 10.1016/j.tips.2005.12.001. View

17.

Andrade V, Guerra M, Jardim C, Melo F, Silva W, Ortega J . Nucleoplasmic calcium regulates cell proliferation through legumain. J Hepatol. 2011; 55(3):626-635. PMC: 3158841. DOI: 10.1016/j.jhep.2010.12.022. View

18.

Cao F, Gao F, Xu A, Chen Z, Chen S, Yang H . Regulation of spinal neuroimmune responses by prolonged morphine treatment in a rat model of cancer induced bone pain. Brain Res. 2010; 1326:162-73. DOI: 10.1016/j.brainres.2010.02.039. View

19.

Ungard R, Seidlitz E, Singh G . Inhibition of breast cancer-cell glutamate release with sulfasalazine limits cancer-induced bone pain. Pain. 2013; 155(1):28-36. DOI: 10.1016/j.pain.2013.08.030. View

20.

Kumar V, Mahal B . NGF - the TrkA to successful pain treatment. J Pain Res. 2012; 5:279-87. PMC: 3442742. DOI: 10.2147/JPR.S33408. View